Imvax
Latest round
- Series C
Last raised
- Jul 2020
Total raised
- $137M
Investors
- 5
About Imvax
Imvax, Inc.Founded in 2015, Imvax, Inc. specializes in immunotherapy for solid tumors, headquartered in Philadelphia, US.Imvax specializes in developing personalized, whole tumor-derived immunotherapies aimed at harnessing the body’s immune response to combat solid tumors. Their flagship product, developed through the Goldspire® platform, captures the full antigen signature of a patient's tumor, allowing for tailored treatment that stimulates both innate and adaptive immunity against remaining cancer cells. The company has reported promising clinical data for its therapies in glioblastoma and has preclinical advancements in multiple other solid tumors, targeting a diverse pipeline of treatments.Imvax's revenue structure primarily revolves around B2B partnerships and collaborations with healthcare institutions and research organizations focused on oncology. The company generates revenue through the sale of its proprietary immunotherapy products, particularly focusing on the flagship Goldspire® platform, which is tailored to individual patients' tumor profiles. Transactions typically involve partnerships with hospitals and clinical research entities that incorporate Imvax’s therapies into their treatment protocols.In January 2025, Imvax, Inc. The company plans to launch new immunotherapy products based on advancing its pipeline, targeting broader geographic expansion into Europe and North America by 2026.
Who invested in Imvax
5 investors across 2 rounds
See all investors in Imvax
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Imvax
Who invested in Imvax?
Imvax has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Imvax raised?
Imvax has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Imvax last raise money?
Imvax's most recent round on record is a Series C, in Jul 2020.
What does Imvax do?
Imvax is a biotechnology company.
Where is Imvax headquartered?
Imvax is headquartered in Philadelphia, US.
Which VCs invest in companies like Imvax?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Imvax's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Imvax? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.